Moderna’s leading vaccine prototype in the US, was the first to enter human trials, and the first to complete Phase 1 in the country.
Tests in 45 healthy volunteers found the virus triggered immune responses, measured by antibody levels, and did not cause any serious side effects, even though more than half of trial participants had mild reactions like fatigue, chills, headaches and aches at the injection site.
The results released yesterday involved three doses of the vaccine, tested in groups of 15 volunteers aged 18-55 who got two shots, 28 days apart. The groups tested 25, 100 or 250 micrograms of the vaccine.
If the next phase of testing in more people goes well, the company will be on track to make 500 million a year, with the goal of 1 billion by the end of 2021.
Experts say a vaccine is needed to put an end to the pandemic that has sickened millions and caused nearly 575,000 deaths worldwide.
‘The world urgently needs vaccines to protect against COVID-19,’ said Dr Lisa Jackson of Kaiser Permanente Washington Health Research Institute in Seattle and lead author of the study.